Oh no_老虎社区_美港股上老虎

sgrs
2021-12-20

Oh no

Intercept Pharma Shares Stumble After Delay in Trial Data

Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical

Intercept Pharma Shares Stumble After Delay in Trial Data

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693603001,"tweetId":"693603001","gmtCreate":1640009853269,"gmtModify":1640009853629,"author":{"id":3582199304143416,"idStr":"3582199304143416","authorId":3582199304143416,"authorIdStr":"3582199304143416","name":"sgrs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Oh no</p></body></html>","htmlText":"<html><head></head><body><p>Oh no</p></body></html>","text":"Oh no","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693603001","repostId":1134420562,"repostType":4,"repost":{"id":"1134420562","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640009445,"share":"https://www.laohu8.com/m/news/1134420562?lang=&edition=full","pubTime":"2021-12-20 22:10","market":"us","language":"en","title":"Intercept Pharma Shares Stumble After Delay in Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1134420562","media":"Dow Jones","summary":"Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical ","content":"<p>Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.</p>\n<p>Intercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.</p>\n<p>In premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.</p>\n<p>Michelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.</p>\n<p>\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.</p>\n<p>The company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intercept Pharma Shares Stumble After Delay in Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntercept Pharma Shares Stumble After Delay in Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 22:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.</p>\n<p>Intercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.</p>\n<p>In premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.</p>\n<p>Michelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.</p>\n<p>\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.</p>\n<p>The company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ICPT":"Intercept Pharmaceuticals"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134420562","content_text":"Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.\nIntercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.\nIn premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.\nMichelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.\n\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.\nThe company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":560,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}